Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ahmed Elzoghby, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, EgyptPrincipal Investigator10/2014Pharmaceutical Sciences (Cancer Nanotechnology)
Faculty of Pharmacy, Alexandria University, EgyptPhD09/2012Pharmaceutical Sciences (Cancer Nanotechnology)
Faculty of Pharmacy, Alexandria University, EgyptMaster09/2009Pharmaceutical Sciences (Drug Delivery)
Faculty of Pharmacy, Alexandria University, EgyptBachelor06/2003Pharmaceutical Sciences

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. IC/3/April/2017/DNPI15053 (Ahmed Elzoghby) Apr 3, 2017 - Apr 3, 2019
    Science& Technology Development Fund (STDF), Ministry of Scientific Research, Egypt
    Synthesis and Evaluation of Drug-Polymer Conjugate Nano-Micelles as Emerging Platform for Targeted Brain Tumor Therapy
    Role: Co-Investigator
  2. TC/3/April/2013/DNPI5731 (Ahmed Elzoghby) Apr 20, 2013 - Apr 20, 2016
    Science & Technology Development Fund (STDF), Ministry of Scientific Research, Egypt
    Inhalable Anti-Cancer Drug-Loaded Nanocomposites for Enhanced Lung Cancer Targeting
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kamel NM, Samaha MW, Elzoghby AO, El-Kimary EI. Sensitive Inexpensive HPLC Determination of Novel Anticancer Combination in Nanoparticles and Rat Plasma: Pharmacokinetic Application. J Chromatogr Sci. 2020 Feb 11. PMID: 32043118.
    Citations:    
  2. Yu HP, Liu FC, Umoro A, Lin ZC, Elzoghby AO, Hwang TL, Fang JY. Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency. J Nanobiotechnology. 2020 Jan 31; 18(1):25. PMID: 32005196.
    Citations:    
  3. Hafez DA, Elkhodairy KA, Teleb M, Elzoghby AO. Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy. Expert Opin Drug Deliv. 2020 Mar; 17(3):279-285. PMID: 31997666.
    Citations:    
  4. Ali OM, Bekhit AA, Khattab SN, Helmy MW, Abdel-Ghany YS, Teleb M, Elzoghby AO. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy. Colloids Surf B Biointerfaces. 2020 Apr; 188:110824. PMID: 32023511.
    Citations:    
  5. Kamel NM, Helmy MW, Samaha MW, Ragab D, Elzoghby AO. Multicompartmental lipid-protein nanohybrids for combined tretinoin/herbal lung cancer therapy. Nanomedicine (Lond). 2019 09; 14(18):2461-2479. PMID: 31456481.
    Citations:    
  6. Gaber M, Hany M, Mokhtar S, Helmy MW, Elkodairy KA, Elzoghby AO. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2019 Dec; 105:110099. PMID: 31546395.
    Citations:    
  7. Abdelmoneem MA, Elnaggar MA, Hammady RS, Kamel SM, Helmy MW, Abdulkader MA, Zaky A, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma. ACS Appl Mater Interfaces. 2019 Jul 31; 11(30):26731-26744. PMID: 31268657.
    Citations:    
  8. Lin CY, Hsu CY, Elzoghby AO, Alalaiwe A, Hwang TL, Fang JY. Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomater. 2019 05; 90:350-361. PMID: 30951898.
    Citations:    
  9. Elzoghby AO. Pharmaceutical nanotechnology in Egypt: diverse applications and promising outcomes. Nanomedicine (Lond). 2019 03; 14(6):649-653. PMID: 30693819.
    Citations:    
  10. Zayed DG, Ebrahim SM, Helmy MW, Khattab SN, Bahey-El-Din M, Fang JY, Elkhodairy KA, Elzoghby AO. Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids: covalent coupling and phospholipid complexation approaches. J Nanobiotechnology. 2019 Jan 19; 17(1):7. PMID: 30660179.
    Citations:    
  11. Zayed DG, AbdElhamid AS, Freag MS, Elzoghby AO. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging. Nanomedicine (Lond). 2019 02; 14(3):225-228. PMID: 30652951.
    Citations:    
  12. Abdelaziz HM, Elzoghby AO, Helmy MW, Samaha MW, Fang JY, Freag MS. Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells. Int J Nanomedicine. 2019; 14:499-517. PMID: 30666110.
    Citations:    
  13. Sabra SA, Sheweita SA, Haroun M, Ragab D, Eldemellawy MA, Xia Y, Goodale D, Allan AL, Elzoghby AO, Rohani S. Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells. J Pharm Sci. 2019 May; 108(5):1713-1725. PMID: 30528944.
    Citations:    
  14. Elzoghby AO, Freag MS. Toward improving drug delivery research in Egypt: Cancer Nanotechnology Research Laboratory (CNRL) as a role model. Drug Discov Today. 2019 02; 24(2):361-363. PMID: 30439448.
    Citations:    
  15. Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine (Lond). 2018 10; 13(19):2377-2395. PMID: 30346255.
    Citations:    
  16. AbdElhamid AS, Zayed DG, Helmy MW, Ebrahim SM, Bahey-El-Din M, Zein-El-Dein EA, El-Gizawy SA, Elzoghby AO. Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine (Lond). 2018 10; 13(20):2637-2656. PMID: 30338705.
    Citations:    
  17. Gaber M, Mabrouk MT, Freag MS, Khiste SK, Fang JY, Elkhodairy KA, Elzoghby AO. Protein-polysaccharide nanohybrids: Hybridization techniques and drug delivery applications. Eur J Pharm Biopharm. 2018 Dec; 133:42-62. PMID: 30300719.
    Citations:    Fields:    
  18. Elgohary MM, Helmy MW, Mortada SM, Elzoghby AO. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Nanomedicine (Lond). 2018 09; 13(17):2221-2224. PMID: 30265215.
    Citations:    Fields:    
  19. Abd Elwakil MM, Mabrouk MT, Helmy MW, Abdelfattah EA, Khiste SK, Elkhodairy KA, Elzoghby AO. Inhalable lactoferrin-chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma. Nanomedicine (Lond). 2018 08; 13(16):2015-2035. PMID: 30191764.
    Citations:    Fields:    Translation:HumansAnimalsCells
  20. Anwar DM, Khattab SN, Helmy MW, Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO. Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma. Bioconjug Chem. 2018 09 19; 29(9):3026-3041. PMID: 30110148.
    Citations:    Fields:    
  21. Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J Control Release. 2018 10 10; 287:78-93. PMID: 30138716.
    Citations:    Fields:    
  22. El-Lakany SA, Elgindy NA, Helmy MW, Abu-Serie MM, Elzoghby AO. Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer. Expert Opin Drug Deliv. 2018 09; 15(9):835-850. PMID: 30067113.
    Citations:    Fields:    
  23. AbdElhamid AS, Helmy MW, Ebrahim SM, Bahey-El-Din M, Zayed DG, Zein El Dein EA, El-Gizawy SA, Elzoghby AO. Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. Nanomedicine (Lond). 2018 Aug 03. PMID: 30073915.
    Citations:    Fields:    
  24. Elgohary MM, Helmy MW, Abdelfattah EA, Ragab DM, Mortada SM, Fang JY, Elzoghby AO. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy. J Control Release. 2018 09 10; 285:230-243. PMID: 30009892.
    Citations:    Fields:    
  25. Chen CH, Chen CJ, Elzoghby AO, Yeh TS, Fang JY. Self-assembly and directed assembly of lipid nanocarriers for prevention of liver fibrosis in obese rats: a comparison with the therapy of bariatric surgery. Nanomedicine (Lond). 2018 07; 13(13):1551-1566. PMID: 29998778.
    Citations:    Fields:    Translation:HumansAnimals
  26. El-Far SW, Helmy MW, Khattab SN, Bekhit AA, Hussein AA, Elzoghby AO. Folate conjugated vs PEGylated phytosomal casein nanocarriers for codelivery of fungal- and herbal-derived anticancer drugs. Nanomedicine (Lond). 2018 06; 13(12):1463-1480. PMID: 29957120.
    Citations:    Fields:    Translation:HumansAnimalsCells
  27. Kabary DM, Helmy MW, Abdelfattah EA, Fang JY, Elkhodairy KA, Elzoghby AO. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma. Eur J Pharm Biopharm. 2018 Sep; 130:152-164. PMID: 29964122.
    Citations:    Fields:    Translation:HumansAnimalsCells
  28. Sallam MA, Elzoghby AO. Flutamide-Loaded Zein Nanocapsule Hydrogel, a Promising Dermal Delivery System for Pilosebaceous Unit Disorders. AAPS PharmSciTech. 2018 Jul; 19(5):2370-2382. PMID: 29882189.
    Citations:    Fields:    
  29. Kabary DM, Helmy MW, Elkhodairy KA, Fang JY, Elzoghby AO. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B Biointerfaces. 2018 09 01; 169:183-194. PMID: 29775813.
    Citations:    Fields:    
  30. Sabra SA, Elzoghby AO, Sheweita SA, Haroun M, Helmy MW, Eldemellawy MA, Xia Y, Goodale D, Allan AL, Rohani S. Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. Eur J Pharm Biopharm. 2018 Jul; 128:156-169. PMID: 29689288.
    Citations:    Fields:    Translation:HumansAnimalsCells
  31. Liu FC, Yu HP, Lin CY, Elzoghby AO, Hwang TL, Fang JY. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J Nanobiotechnology. 2018 Mar 30; 16(1):35. PMID: 29602314.
    Citations:    Fields:    Translation:HumansAnimalsCells
  32. El-Far SW, Helmy MW, Khattab SN, Bekhit AA, Hussein AA, Elzoghby AO. Phytosomal bilayer-enveloped casein micelles for codelivery of monascus yellow pigments and resveratrol to breast cancer. Nanomedicine (Lond). 2018 03; 13(5):481-499. PMID: 29376765.
    Citations:    Fields:    
  33. Freag MS, Elzoghby AO. Protein-inorganic Nanohybrids: A Potential Symbiosis in Tissue Engineering. Curr Drug Targets. 2018; 19(16):1897-1904. PMID: 29076428.
    Citations:    Fields:    
  34. Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, Kabary DM, Freag MS, Samaha MW, Mortada SM, Elkhodairy KA, Fang JY, Elzoghby AO. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018 01 10; 269:374-392. PMID: 29180168.
    Citations: 4     Fields:    Translation:HumansAnimals
  35. Elzoghby AO, El-Lakany SA, Helmy MW, Abu-Serie MM, Elgindy NA. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. Nanomedicine (Lond). 2017 Dec; 12(24):2785-2805. PMID: 29094642.
    Citations:    Fields:    Translation:HumansAnimalsCells
  36. Chen CH, Huang TH, Elzoghby AO, Wang PW, Chang CW, Fang JY. Squarticles as the nanoantidotes to sequester the overdosed antidepressant for detoxification. Int J Nanomedicine. 2017; 12:8071-8083. PMID: 29138563.
    Citations:    Fields:    Translation:Animals
  37. Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int J Pharm. 2017 Aug 30; 529(1-2):178-192. PMID: 28663087.
    Citations:    Fields:    Translation:HumansAnimalsCells
  38. Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA. Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy. Pharm Res. 2017 Sep; 34(9):1956-1969. PMID: 28643236.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  39. Gaber M, Medhat W, Hany M, Saher N, Fang JY, Elzoghby A. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes. J Control Release. 2017 05 28; 254:75-91. PMID: 28365294.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  40. Elzoghby A, Freag M, Mamdouh H, Elkhodairy K. Zein-based Nanocarriers as Potential Natural Alternatives for Drug and Gene Delivery: Focus on Cancer Therapy. Curr Pharm Des. 2017; 23(35):5261-5271. PMID: 28641543.
    Citations:    Fields:    
  41. Elzoghby AO. Editorial: Polymeric Nanocarriers as Robust Platforms for Cancer Therapy. Curr Pharm Des. 2017; 23(35):5211-5212. PMID: 29110600.
    Citations:    Fields:    
  42. Sabra S, Abdelmoneem M, Abdelwakil M, Mabrouk MT, Anwar D, Mohamed R, Khattab S, Bekhit A, Elkhodairy K, Freag M, Elzoghby A. Self-Assembled Nanocarriers Based on Amphiphilic Natural Polymers for Anti- Cancer Drug Delivery Applications. Curr Pharm Des. 2017; 23(35):5213-5229. PMID: 28552068.
    Citations:    Fields:    
  43. Elzoghby AO, Hemasa AL, Freag MS. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging. J Control Release. 2016 12 10; 243:303-322. PMID: 27794493.
    Citations: 6     Fields:    Translation:HumansAnimals
  44. El-Lakany SA, Elzoghby AO, Elgindy NA, Hamdy DA. HPLC Methods for Quantitation of Exemestane-Luteolin and Exemestane-Resveratrol Mixtures in Nanoformulations. J Chromatogr Sci. 2016 Sep; 54(8):1282-9. PMID: 27130876.
    Citations:    Fields:    Translation:Humans
  45. Elzoghby AO, Abd-Elwakil MM, Abd-Elsalam K, Elsayed MT, Hashem Y, Mohamed O. Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery. Curr Pharm Des. 2016; 22(22):3305-23. PMID: 26845323.
    Citations: 2     Fields:    
  46. Elzoghby A. Editorial (Thematic Issue: Nanocarriers Based on Natural Polymers as Platforms for Drug and Gene Delivery Applications). Curr Pharm Des. 2016; 22(22):3303-4. PMID: 27165162.
    Citations:    Fields:    Translation:HumansAnimals
  47. Elzoghby AO, Vranic BZ, Samy WM, Elgindy NA. Swellable floating tablet based on spray-dried casein nanoparticles: Near-infrared spectral characterization and floating matrix evaluation. Int J Pharm. 2015 Aug 01; 491(1-2):113-22. PMID: 26095913.
    Citations: 1     Fields:    
  48. Elzoghby AO, Elgohary MM, Kamel NM. Implications of protein- and Peptide-based nanoparticles as potential vehicles for anticancer drugs. Adv Protein Chem Struct Biol. 2015; 98:169-221. PMID: 25819280.
    Citations: 3     Fields:    Translation:Humans
  49. Elgindy NA, Samy WA, Elzoghby AO. Casein-based micelles: a novel vector for delivery of the poorly soluble anticancer drug, flutamide? Ther Deliv. 2014 Jan; 5(1):7-9. PMID: 24341810.
    Citations:    Fields:    Translation:HumansAnimals
  50. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013 Dec 28; 172(3):1075-91. PMID: 24096021.
    Citations: 18     Fields:    Translation:HumansAnimals
  51. Elzoghby AO, Saad NI, Helmy MW, Samy WM, Elgindy NA. Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats. Eur J Pharm Biopharm. 2013 Nov; 85(3 Pt A):444-51. PMID: 23872177.
    Citations: 3     Fields:    Translation:Animals
  52. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. Pharm Res. 2013 Oct; 30(10):2654-63. PMID: 23739989.
    Citations: 1     Fields:    Translation:Animals
  53. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics. Int J Nanomedicine. 2013; 8:1721-32. PMID: 23658490.
    Citations: 4     Fields:    Translation:Animals
  54. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: formulation, characterization, and in vivo pharmacokinetics. Eur J Pharm Biopharm. 2013 Aug; 84(3):487-96. PMID: 23403015.
    Citations: 2     Fields:    Translation:Animals
  55. Elzoghby AO, Samy WM, Elgindy NA. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm Res. 2013 Feb; 30(2):512-22. PMID: 23135815.
    Citations: 5     Fields:    Translation:Cells
  56. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012 Jul 10; 161(1):38-49. PMID: 22564368.
    Citations: 30     Fields:    Translation:HumansAnimals
  57. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012 Jan 30; 157(2):168-82. PMID: 21839127.
    Citations: 79     Fields:    Translation:HumansAnimals
  58. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation. Drug Dev Ind Pharm. 2011 Apr; 37(4):446-55. PMID: 21446829.
    Citations: 4     Fields:    Translation:Cells
  59. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled flutamide release. Int J Pharm. 2011 Jun 15; 411(1-2):113-20. PMID: 21457767.
    Citations: 3     Fields:    
  60. Elzoghby AO, El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011 Aug 10; 153(3):206-16. PMID: 21338636.
    Citations: 14     Fields:    Translation:HumansAnimals
  61. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. Drug Dev Ind Pharm. 2011 Jul; 37(7):754-64. PMID: 21204753.
    Citations: 2     Fields:    Translation:Humans
  62. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide. Eur J Pharm Biopharm. 2010 Feb; 74(2):397-405. PMID: 19944160.
    Citations: 9     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Elzoghby's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (196)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.